Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 6, Number 6—December 2000

Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Figure 1

Yearly efficacy of drug therapy. Results of praziquantel treatment (solid bars) or metrifonate treatment (shaded bars) for Schistosoma haematobium infection in the Msambweni area during 1984 to 1992. Cure rates (conversion from egg-positive to egg-negative urine in annual follow-up testing) are shown for all egg-positive cases, by year of treatment. Only metrifonate therapy was given in 1987, and no treatment was given in 1988.

Figure 1. Yearly efficacy of drug therapy. Results of praziquantel treatment (solid bars) or metrifonate treatment (shaded bars) for Schistosoma haematobium infection in the Msambweni area during 1984 to 1992. Cure rates (conversion from egg-positive to egg-negative urine in annual follow-up testing) are shown for all egg-positive cases, by year of treatment. Only metrifonate therapy was given in 1987, and no treatment was given in 1988.

Main Article

Page created: December 17, 2010
Page updated: December 17, 2010
Page reviewed: December 17, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external